Enhanced thrombolysis, reduced coronary reocclusion and limitation of infarct size with liposomal prostaglandin E1in a canine thrombolysis model  by Feld, Steven et al.
In experimestal models of temporary sorontuy cxhh.m, the 
severity and duntion of ischemia we the principal determi- 
nants of the severity of reversible myocardial dysfunction after 
reperfusioa (myocardial stunning) (1) as well as the extent 
of irrevcrsiblc myocardial damage that ensues (2). Limitation 
of myocardial necrosis depends on the prompt restoration of 
blood flow to an occluded coranitv artery (.%I), Thrombolytic 
therapy with intravenous recombinant issue-type plasminogen 
activator (t-PA) results in infarct-related artery patency in 70% 
to 8S% of ptients with acute myocardial infarction within 
90 min of infusion (5-9). However, only -50% of treated 
patients have normal coronary flow on early angiography (10). 
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and subsequent reocclusion is not infrequent and is associated 
with an adverse prognosis (1 l-13), 
Efforts to identify safe and efficacious adjunctive pharma- 
cologic agents that will accelerate the time to thrombolysis, 
improve coronary flow and prevent reocclusion proceed in 
earnest. Preliminary experience in our laboratory has sug- 
gested that liposomal prostaglandin E, inhibits platelets and 
leukocytes in dogs for 290 min when administered by intrave- 
nous bolus at a dose of 0.5 pg./kg body weight given over 
10 min. Moreover, we have found that a similarly administered 
dose of liposomal prostaglandin E, at the onset of coronary 
occlusion and repeated 90 min later limits infarct size without 
significantly affecting hemodynamic status in a canine infarc- 
tion model that consisted of 2 h of coronary ischemia followed 
by a 2-h period of reperfwsion (14). 
In the present study, we used a more clinically relevant 
canine model with copper coil-induced coronary artery 
thrombi (15) to test the hypothesis that liposomal prostag- 
landin E, given intravenously I h after clot maturation and just 
before intravenous streptokinase and heparin would accelerate 
073.51097/94/$7.00 
the time to thrombolysis and prevent reocchrsion during a 2-h 
reperfusion period, Beading to 9 reductioll iI1 infarct size. 
s 
either gender weighing 25 to 40 kg were anesthetized. ventilated 
and placed on continuous electrocardiographic monitoring. An- 
csthesia was maintained with pentobarbital. P ncuronium bto- 
mide (0.04 nag&) was given intravenously before thoracotomy, 
and a tl~a~~ltet~al~ce infusion of lidocaine (1 ~~l~~rli~i after a 
l-nag/kg bolus) or lidocaine plus procainamide (2.8 mg/kg per h 
after ;\ l7-mgdkg bolus over I 11) was administered for arrhythmia 
prophyl;utiS iId control of lteouoclyn;rnlici~l~~~ signiticant \TFIil’iCU- 
lar ectopic beats. A left thoracotomy was performed in the fifth 
intercostal SPXC, and the hsart was suspended in ii prric;rrdi;d 
cradle. The left itnteritu descending coronary artcry BQS gently 
disscctrd fret of Surrounding tissue distal to the origin of its first 
diagonal branch, and a cylindric Doppler How probe was placed 
around the isohtcd scgmcnt. Visible picardial co11;ucral vcssc!s 
were tied off outside the anticipated ischcmic region. Cathcteos 
were inserted into the left atrium and left ventricle through stab 
wounds in the left atrial appendage and left ventricular pex, 
respectively, and connected topressure transducers. A second 
catheter was placed in the left atrium for delivery ofradioactive 
microspheres. Theleft external jugular vein, left internal carotid 
artery and right femoral rtery were also cannulated. A catheter 
was advanced through t e femoraf sheath to the thoracic aorta fat 
aortic pressure r cording and arterial blood sampling during 
microsphere injection. 
Measurements. Baseline hemodynamic measurements, in- 
cluding heart rate and left atrial. left ventricular nd aortic 
pressures were obtained. Left anterior descending coronary 
blood flow velocity was recorded inkilohertz from a calibrated 
pulsed Doppler flow probe. Regional myocardial blood Row 
was measured using 0.1 mCi of 15pm radioactive micro- 
spheres labeled with one of five different isotopes (NEN- 
TRACY, Dupont). One milliliter containing 2 to 3 million 
microspheres was injected rapidly into the left atrium, followed 
by a saline flush. The microspheres were sonicated for 3 min at 
37°C before injection. Withdrawal of reference arterial blood 
from the thoracic aorta t a constant rate of 7 ml/min using a 
calibrated Harvard pump was begun just before the micro- 
sphere injection and maintained for 3 min. 
After baseline data were obtained, catheterization of the 
left coronary artery using a 6F 3.5 left Judkins catheter inserted 
through the carotid sheath was performed. Contrast medium 
was then injected to confirm the position of the Doppler flow 
probe distal to the origin of the first diagonal branch. A 
0.014-in. (0.036-cm) guide wire was advanced beyond the 
Doppler probe into the distal left anterior descending coronary 
artery. The Doppler probe was temporarily removed, and a 
copper coil was introduced into the coronary artery over the 
guide wire and positioned in the exposed arterial segment just 
distal to the Doppler probe. A silk ligature held the coil in 
place. The copper coil was prepared 48 to 72 h in advance by 
~Vrappiolg %- auge uncoated copper wire around a 1%gauge 
needle for five complete turns. 
An occlusive thrombus formed within 10 min in most dogs. 
rcsuhing in cyanosis and paradoxic Systolic expansion i the 
ischenlic region. @?oronary occhsion was ConfimmCd !q~ &e 
absence of Doppler Bow. After 80 min of occlusion, hcmody- 
namic and myocardial b ood flow determinations were ree- 
peated. After 50 min of clot maturation, dogs were randomly 
assigned to receive either liposomal prostaglaudin E, (TkC 
C-53) aF a dose of 2.0 pg of prostaglandin El/kg or placebo 
(0.01 mollliter buffered acetate solution) administered through 
the jugular vein by constant infusion for IO min. The TLC C-53 
waS supplied by The Liposome Company and consisted of 20 
,u@nB of prostaghmdin E, and 4 mg/mP ofegg p!losplratidyl- 
ChliW in t).Ol mol/litcr acetate bulfcr. ‘fhc mean particfc 
diamctcr WitS ~WWII O.Oj iald 0.5 p.~. After completion of
the infusion, heparin (200 U/kg) was given by intrav~~~~us 
bolus. A streptokinasc infusion (5,000 U/kg) was administered 
for h0 min. 
~hWNP?O!)‘Sk tilllC W;IS dcfilIcd iIS thC time f’l’O~~ IIIC WSC~ 
of streptokinasc infusion to the return of mean Doppler Wow 
velocity to at least 50% of its baseline value. lf How did not 
return within 2 h of thrombolytic herapy (3 h of permanent 
coronary occlusion i cluding the period of clot maturation), 
the artery was considered wt to have recanalized. and the dog 
was killed. Dogs with successful thrombolysis were monitored 
for a period of 2 h after the onset of reperfusion with a 
continuous Doppler r cording of phasic and mean coronary 
blood flow velocity. Eeft anterior descending coronary artcry 
flow velocities during the entire reperfusion period were 
classified into one of four categories reflecting progrcssivc 
impairment in blood Now: I) Full ,@IJ was defined as st;~hlc 
coronary perfusion with mean fiow velocities >7tPX of hasc- 
line. 2) R~~i~rced &K was identilicd bya stable flow pattern 
with a mean velocity of 30% to 70% of baseline or by the 
presence ofcyclic flow variations defined as spontaneous cyclic 
reductions in coronary flow to ~50% of baseline. 3) f.o~jflo~’ 
occurred when, in addition to cyclic flow, velocities were 
persistently reduced to ~30% of baseline for a period of 
>20 min. 4) Reoccl~uio~ was characterized by azero-flow state 
that persisted throughout the remainder of the reperfusion 
period (modilied from Willerson et al. [IO]). 
J-femodynamic and myocardial b ood flow measurcmcnts 
were obtained at baseline, during clot maturation, after epcr- 
fusion and before uthanasia. Activated clotting time (I-kmo- 
chron 400, International Technidyne Corp.) and the hemalo- 
crit were determined at baseline, during streptokinasc 
infusion, at the onset of reperfusion rcompletion Of StrCp- 
t&&e infusion for dogs that did not have rcperfusion and 
after 2 11 ofreperfusion r 3 h of permanent occlusion. Animals 
were killed by injection of a supersaturated potaSSiUm chhide 
solution after sedation. The heart was quickly cxciSed and 
washed with water. The coil was removed through an i CiSiOn 
in the arterial wall, and a cannula was inserted for perfusion of 
the distal left anterior descending coronary artery with a 1% 
solution of triphenyltetrazolium chloride bufYercd toa PH of 
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8.5 and simultaneous infusion of the aortic root with Evans 
blue at equal pressure of 100 mm fig for 3 to 5 min. The left 
ventricle was sliced in a breadloaf fashion into l-cm thick 
sections from base to apex, and the slices were weighed. The 
risk region containing residual viabtz tissue stained brick red, 
whereas infarcted tissue remained unstained nd tan in ap 
pearance (17,18). The control region stained blue. 
Both surfaces of each ventricular slice were traced on 
acetate film to show the histochemical demarcation f the 
infarct, risk and control regions. Their respective ar as were 
planimetered and muttiplied by the slice weight to determine 
infarct size as a percent of myocardium at risk and total left 
ventricu9ar mass. The ventricular slices were then subdivided 
endocardial, midmy~ardial and epicardial pieces. 
hed and counted for radioactivity together 
arterial blood samples in an ~ut(~mat~d 
gamma scintillation counter (1282 Cumpu~amma, LKB- 
Wallac, Turku, Finland) whose windows were mdjustcd 
for the pak emi~i~n of the is used, creating a precise 
(99,20). ~cpresentative 
Ies from histochemically stained ischemic and 
were chosen for comparison f myocardial 
istochemically defined ischemic 
reg9on whose transmural flow during coronary occlusion was 
~0.4 ml/mm per g of myocardium were excluded because of
the presence ofcollateral flow. Mean transmural blood flow 
~0.4 ml/min per g has been shown to correlate with severe 
functional impairment (akinesia or dyskinesia) of the involved 
myocardium (21) and corrcspnds to the level of flow at which 
myoeardial necrosis i first evident (22,23). 
Myeloperoxidase ctivity, an index of the infiltration of 
neutrophils nto ischemic myocurdium, was assayed according 
method of Mullane et al. (24). ~y~ardial samples 
ng 20 to $6 mg obtuin~d from the infarct zone, the risk 
region and the border zone btwcen the two, as well as the 
nonisehmie region, were frozen in liquid nitrogen. Thawed 
tissue wns fended in a solution eontwining 3 ml of 50 mmol! 
titer potasshun p~~h~te b O.%% h~d~l~methyi~- 
monium bromide and was 
fuged at 4O,O&)g forIS min. 
eve tiiuity was defined as the amount required to
1~09 of peroxidejmin at 30°C. 
e experimental procedure described conforms t3 the 
“Position of the Amerisan Heart Association on Research 
d by the Association i  November 1984. 
Data were xpressed as mean value t 9 
SD. DifTerences in mean values between the placebo and TLC 
fXi3 WUps were assessed bythe unpaired two-tailed t test, 
For multiple comparison procedures, including hemodynamic 
and coronary Sow data, two-factor ana9ysis of variance fol- 
lowed by the Newman-Keuls multiple-range test were per- 
formed. The chi-square t st was used to analyze categoric data 
for significant differences among comparison groups. 
of covariance was performed to compare infarct si 
placebo and TLC C-53 groups using collateral b ood 
covariate; p < 0.05 was considered significant. 
Of the 30 dogs studied, 14 were excluded from ana9ysis. 
Seven dogs had cardiac arrest and were unable to be resusci- 
tated with three attempts atdefi~ri9~ation. In a99 seven cases* 
ventricular ~br~99ation occurred 
insertion or shuttle t~~r~~ft~r~ t 
or placebo infusion. la four 
flow after co99 i~s~rti~~ iadi
hsd not formed witbin 20 mtn. 
Sixteen dogs were suitable for ana9ysis, eight of which were 
randomly assigned toreceive T C-53 aud eight to receive 
Pla 
emodynami~ variables, includ- 
ing heart rate, mean aortic 
atrial pressure and left ventri 
pressures for placeb- and 
similar at baseline, durin 
reperfusion period (Table 
heart rate d clined signific 
of re~rfusion, and the 
arterial nd left ventricu9ur pressures in both groups during the 
tency~ All eight dogs treated 
on of their coronary thrombus, 
only 9ive of eight placebo-treated dogs achieved clot 
en on9y dogs that had recanalization were considered, 
there was  trend toward more rapid thrombolysis with TLC 
C-53 treatment (46.6 f 8.8 min) than with placebo (54.2 f- 
21.9 min), which was not significant. Because all dogs given 
TLC C-53 had reperfusion butthree of eight in the placebo- 
treated group did not, it is possible that delayed recanalization 
occurred with TLC C-53 treatment of arteries that might 
otherwise not have reperfused with placebo. Therefore, dogs 
that did not achieve recanaiization during the 2-h observation 
period after clot maturation were assigned a thrombolysis time 
of 120 min. With this adjustment to account for the observed 
difference in recanalization rate, a significant difference in
thrombolysis t me between the two treatment groups was 
found. Thrombolysis time was accelerated from 78.9 + 
37.9 min in the placebo-treated group to 46.6 +_ 8.8 min in the 
TLC C-53-treated group (p < 0.05). During the reperfusion 
period, one additional p acebo-treated doghad reocclusion. 
Coronary patency atthe eompietion fthe protocol, before 
euthanasia w s significantly greater (p = 0.02) with TLC C-53 
(100%) than with p9acebo (50%). Further characterization of 
left anterior descending coronary artery flow during repetfu- 
PrdreimenP 
10 min 50 min 
Rrperfusion No 
Treatment Posttreatment &perfusion 
(htl min) (65 min) 10 min 60 min 120 min (180 min) 
x -‘- 3 
S”2 
‘p i II.&5 (TLC C-53 vs. placeho). ‘tp K 0.05 (VA. hhs). D;II;I prcacntcd iIrC mcau v&e 1 SD. I-IR zi heart rate; LA = left atrial; LAD = left anterior dcsce~~ding 
coronary artery; LV = left ventricular; MAP = mca~ aortic pressure; TLC C-S3 = liposomal prostaglandin E,. 
sion into states of low flow (<30% 
(30% to 70% of baseline) or fu 
remaining 37.5% had a modest reduction in fl 
fusion compared with baseline. Three pla 
C-53-treated ogs de~o~st~ated cyclic 
use of the small number of dogs in each group demon- 
ing cyclic flow. 
In fact, all three placebo-treated dogs with cyclic flows 
oped a persistently low 
lie Mow reductions durin 
one dog, the artery per~ane~tiy reoc- 
severe, persistent reduction in coronary Row that most li 
would have resulted in reocclusion had the reperfusion pe 
been extended >2 y comparison, cyclic flow variations 
Figure 1. Characterization of Dopp- 
ler coronary blood flow for placebo- 
and liposomal prostaglandin El (TLC 
C-53~treated dogs. Categories of 
progressively less severe impairment 
in coronary flow appear from le 
right. Compared with placebo, there 
was significantly less impairmtint to 
coronary blood flow with TLC C-53 
by chi-square analysis (p < 0.05). 
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Q. 
Onset of reperfusion defined by the return of mean Doppler flow to 
XW% of beline. 4 Cyclic flow variations cccurring during the 
rfusion period that demonstrate a lower nadir of flow approaching 
0 in the placeb+treated dog and a much mildrr reduction of flow in 
the TLC C-5.3=-treated dog. LAD = left anterior descending coronary 
artery. 
were relatively mild in the TLC C-53 group and did not lead to 
reocclusion. 
C-S3-treated dogs (Table 
av~itabili~ of ~di~~ctive microspheres. There were no signif- 
icant di&rences between plucebo- and TLC C43-treated 
baseline. During coronary ~cl~sion (before 
C-53 treatment), ischemic zone flow mcasu 
to 11 2 9% of si 
During the reperfcsion period, there was a s~~~i~~nt 
vement in blood flow to the ischemic region in the TLC 
treated group compared with the placebo-treated group. 
‘Ten minutes akr the onset of reperfusion. reactive hyperemia 
occurred in TLC C-B-treated dogs, resulting in ischemic zone 
Ie 2. Trammural Regional Myocardial Blood Flow for Placebo- and Liposomal 
Prostaplandin &-Treated DWS 
LAD IO-min 2-h Reperfusion 
ihp Baseline Occlusion Rcperfusion or 3-b Occlusion’ 
TLC c-s.3 
kchemic region 0.79 2 0. I8 0.16 z 0.05 1.28 2 0.47 0.50 + 0.23 
Control region 0.82 2 0.20 0.70 2 0.x 0.77 2 0.23 Q63 2 0.18 
Ischemickontml 
Flow ratio 0.99 * 0. I8 0.11 t 0.06 1.70 -2 O.SH 0.85 2 0.43 
Placebo 
Ischemic region 0.84 -c 0. I9 0.11 2 0.12 0.81 2 0.49 0.9 c 0.18 
Contml region 1.12 t 0.10 0.99 t 0.2 1 1.03 2 0.25 0.76 f 0.31 
Ischemickwntrol 
Flow ratio 0.80 t 0.23 0.11 ? 0.09 0.77 z 0.35t 0.35 f 0.23 
*For those dogs that did not achieve repetfusion, biood flow was determined after 3 h of permanent coronary 
occlusion. tp < 0.05 (TLC C-53 vs. placebo). Absolute flows are listed for the ischemic and contra! regions in ml/g per 
min. and their ratio is expressed as a decimal. Data presented are mean value 2 SD. Abbreviations as in Table I. 
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Fi 3. Linear rcgrcssion analv- 
sis describing lhr rrhion of ink&t 
size expressed as a percent of the 
area at risk and collateral blood 
flow during cor~~~l~~ occlusion in 
I ischcmic zone. ‘4 sig- E 
flow of 141 -i- 30% of base ine, which corr~~s~o~ded to 170 + 
When all dogs with or without reperfusion arc included, there 
was a trend toward greater impairment in myocardiaI blood 
flow into the ischemic zone after 2 h of reperfusion or 3 h of 
permanent occlusion in the placebo group. Isc 
as a percent of baseline was 66 t 34% for the TLC C-U- 
26 t 18% for the placcbo- 
ischemic region as a percent of 
flow in the contr f 43% for the TLC 
35 + 23% for the placcbo- 
t~a~~~~. Infarct size ex- 
pressed as a percent of the arca at risk was significantly lower 
(p < 0.05) with TLC C-53 (33.3 2 14.4%) than with placebo 
(51.0 t 14.5%). Infarct size in absolute terms was lower with 
TLC C-53 than with placebo (8.0 f 5.2 vs. 14.1 9 7.4 g, 
respectively, p = NS). Infarct size as a percent of left ventric- 
ular mass was also lower for TLC C-53 (6.0 2 3.3%) than for 
placebo (8.8 + 3.6%, p = NS). The area at risk as a percent of 
the left ventricle was similar for TLC C-53 (17.7 2 6.1%) and 
placebo (17.0 2 4.3%). Although postmortem myocardial 
staining occurred at a relatively short interval (-3 h) after 
coronary occlusion, gross examination of myocardial slices 
revealed clear dt!ma,r(ations among the ischemic, risk and 
control regions that was substantiated by regional myocardial 
blood flow measurements. 
Infarct size as a percent of the area at risk was inversely 
related to collateral blood flow into the ischemic zone during 
coronary occlusion (Fig. 3). The correlation was relatively 
weak for the TLC C-5Ftreated group and may have been 
uenced in the placebo-treat 
eared dog with high collater 
epicardial collateral bl 
covariate XCditlg to t 
size (as a percent of ar 
ccbo (p < 0.01) V hen tra~s~~~ral 
collateral blood flow to the ischemic region was ussd as a 
covariate, again infarct size was smaller with TLC C-S3 ( 
0.03). This suggests an independent trea nt ekect of TLC C-53 
in r cing infarct size for any given lcve collateral blood How. 
isuring the activity of the ncutrophil-specific azurophilic 
granule containing myeloperoxidase enzyme is a sensitive 
method for accurately quantifying leukocyte infiltration during 
ischemic myoc~~rdial injury (24). There was a significant reduction 
in enzyme activity in samples of ischemic myocardium obtained 
from the infarct zone (0.18 t 0.16 vs. 0.62 + 0.41 I_J/IOO mg tissue, 
II < 0.05) the area at risk (0.11 f 0.00 vs. 0.45 t- 0.35 U/lo0 
p < 0.01) and the border zone (0.15 -t 0.19 vs. 0.64 t 0.27 lJ 
mg, p < 0.01) with TLC C-53 compared with placebo, res 
tively. There was no significant difference in enzyme content in 
the control regions (0.06 1- 0.08 vs. 0.10 t 0.15 IJIOO mg) of the 
TLC C-S3- and placebo-treated groups, respectively. This would 
indicate a reduction in the number of infiltrating neutrophils in 
the territory rendered ischemic by coronary occlusion after T 
C-53 treatment. 
ostasis. Baseline mean activated clottin 
tre nt groups were similar. Dogs treated wi 
had a significantly greater increase in mean activated clotling 
time after the heparin bolus and the onset of streptokinase 
infusion than dogs given placebo (1,678 j: 803 VS. 362 2 123 s, 
p < 0.05). The activated clotting time measured at the onset of 
reperfusion (or completion of the l-h streprokinase infusion 
for those dogs that did not achieve repOrfusion) v!as higher 
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with TLC C-53 (566 + 444 vs. 362 + 123 s, p = NS). A similar 
trend was een before uthanasia (211 -t 54 vs. 147 -C 75 s). No 
adverse effects on hemostasis that resulted in significant hem- 
orrhage or decline in the hematocrit were encountered in 
either treatment group. 
f myocardial necrosis 
Pr ing with the duration of coronary occlusion by Reimer 
and the demonstration of greater myocardial sa vage 
ocardial function (26) and im- 
after early reperfusion provided 
m~lytic therapy as a means of 
in hurn~~s~ Large clinical trials (10,28- 
tratcd that succ~~ful rc~rfusi~~t~ leads 
to a greater reducti~~u in ~~~~ali~ and improvement in left 
patent infarct-related artery may extend b 
immediate effects on myocardial salvage toinclude subsequent 
limitation ofinfarct expansion a d aneurysm formation during 
ventricular remodeling (35-40) as well as protection from 
sudden death from fatal arr 
ica number of patients with acute 
myocardhl infarction, intracoronary prostagl~ndin E, was 
effective inrestoring coronary flow in two of four patients who 
failed to achieve recanalization with intracoranary st eptoki- 
na,se and resulted in prompt improvement i  left ventricular 
function. Using a canine infarction model, Jugdutt et al. (46) 
admjnistered pr~~stag~~~nd~ns E,, Er and I: in pharmacologic 
hieve a similar reduction in arterial 
t prost~~landins E, and IZ, but not E,, 
n collateral b ood flow and a reduction 
of their short half-life and relative 
dins were infused irectly into the left 
in E,. In the 
in thrombol- 
ysis time and improvement in coronary patency when TLC 
C-53 was administered intravenously befoae thrombolytic her- 
apy. TLC C-53 is a stable preparation of prostaglandin E, 
bound by phospholipid microspheres with less adverse hemo- 
dynamic effects during intravenous e. 1r1 addition, the incor- 
oration af ~r~~st~~l~n~iu E, into lipwmt:s may favor drug 
~~~i~~ to sites of :haugh most intrave- 
nously administere ed by the reticuloen- 
dethelial system, acokinetics and distribution of 
li mes are complex and depend on dose, size and chemical 
composition, especially ipid content (48). These and other 
factors will influence the release of entrapped compounds and 
the ability of limmes to escape the vascular space during 
ViihiS pathologic conditions. To our knowledge the distribu- 
tion of liposomal prostaglandin El in myocardia~ nfarction has 
not been studied. 
The significant ~rolougatiou in the activated clotting time 
during streptokinase infusion with TLC C-5 
tributed to enhanced thrombolysis. ~tbougb 
was not assessed in our study, Vaughan et al. 
that prostaglandin E, inhibits platelet function and accelerates 
-PA in a rabbit jugular vein model of thrombosis. 
illerson et al. (50) de~omstratcd hat li 
prostaglandin El administe~e 
2 r_ldks a~lisbed cyclic tlo 
endothelium-iujurcrt~ c~u uc c~r~~~~~ry ~~rt~~ics~ wherces free 
pros andin E, did not. They 
by coll~geu was inhibi 
whereas 
the present study, not only was thr patcucy mte grcitter w 
TLC C-53 tr~~~tment, but the KS of ~~~~~~~~r~~~c~~t in blo 
flow during the rep~r~usion ad was relatively mild. 
comparison, place~u-treated dogs that succcssful~~ ackicvu 
rec~~~lizatiou of their cosoua~ tbro~~bus often d~ll~o~str~~!c 
clic flow reduction i the reperfusion period, with a 
of flow, extemded periods of How Blow or reocclu- 
C-53, wc also found a sign~~caut inl~rovement i  myocardial 
blood flow to the ischemic region at the microvasc~~~r level
detcrmin~d by intraatrial 
spheres. The improvement i  ow translated into a 
significant reductive ininfarct 
at risk. However, collateral 
to uuui~bemic zone ng coronary occlusion was 
somewhat greater in C-53 group, although the 
difference was not statistically significant. Infarct size has been 
shown to correlate more closely with the ratio of ischemic to 
nonischemic zone flow than absolute ischemic zone flow (51). 
Thus, a relative increase in collateral f ow during coronary 
occlusion in the TLC C-5Ftreated group before treatment 
may have contributed toa reduction in infarct size indepen- 
dent of drug effect. Nonetheless, a treatment effect of TLC 
C-53 was demonstrated for any given level of collateral flow. 
The cause ofiimitation i  infarct size in this tudy appears 
to be multifactorial. The relative importance of significant 
differences in collateral blood ffow during ischemia, duration 
of ischemia and degree of anterograde blood flow during 
reperfusion in the two groups on infarct size is difficult o 
determine. Moreover, a reduction i  infarct size in the TLC 
C-S-treated group may have been the result not only of a 
greater degree of collateral flow during occlusion or an im- 
provement in anterograde coronary flow during reperfusion 
but possibly a direct effect of TLC C-53 on cellular ele 
iuvolved in reperfusion injury. 
The pathogenesis of myocardial injury after reperfusion 
appears toinvolve complex functional interactions of damaged 
endothelial cells and activated leukocytes and mast celfs capa- 
JACC Vol. 244. No. 5 
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ble of free radical generation and release of proteases that 
microvascular damage be 
nentro~l~~~-niyocytc adhesion (54-56). 
whether the diRerences in leukocyte infiltration were tbem- 
selves caused by differences in infarct size in the two groups or 
by an in ndent ctkct of TLC C-53 ~irn~t~ng infiltration of 
leukocyt to isckmic ~~yoc~lrdi~~s~, perhaps by il%teGIlg thr 
qression Of ~~d~~~si~n ~~~~lec~~es on ~~~y~~cytes or XtlVilttA 
icocy of t~~~on~bo~yt~c therapy 
protection by another mechanism. 
study (14) we did not find a differe 
salvage with drug-free liposomcs compared with placebo di- 
luent, whereas liposomal prostaglandin E, administered 
ing coronary occlusion significantly reduced infarct size. 
effect on infarct size of relative (albeit nonsignificant) differ- 
ences in collateral blood flow during coronary occlusion in the 
two groups before randomized treatment with either TLC C-53 
or placebo is a second limitation to interpretation of our 
results. Nonetheless, infarct size was reduced witb TLC C-53 
compared with placebo using either e icardial or transmural 
blood flow as a covariate. 
ConcBusiuns. Liposomal prostaglandin E, (TLC C-53) ad- 
ministered intravenously before tl~rombo~ytic therapy with 
intravenows strep inase and heparin after copper coil- 
induced coronary bosis in a canine model resulted in a 
significant acceleration in thrombolysis time, a greater patency 
rate, a lower incidence of reocclusion and a significant im- 
provement in coronary blood flow during reperfusion. More- 
over, TLC C-53 treatment did not adversely affect either 
hemodynamic variables or hemostasis and led to a reduction in 
infarct size and infiltration of iscbemic myocardium with 
net!trnphils. A clinical trial utilizing TLC C-53 or a similar 
comp”und as an adjunct to thrombolysis with conventional 
thrombolytic agents should be considered. 
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